Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.

Arita Y, Sakata Y, Sudo T, Maeda T, Matsuoka K, Tamai K, Higuchi K, Shioyama W, Nakaoka Y, Kanakura Y, Yamauchi-Takihara K.

Heart Vessels. 2010 Sep;25(5):444-7. doi: 10.1007/s00380-009-1215-5. Epub 2010 Jul 31.

PMID:
20676969
2.

Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.

Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M.

Int J Hematol. 2009 Jul;90(1):99-102. doi: 10.1007/s12185-009-0346-x. Epub 2009 Jun 26.

PMID:
19554396
3.

Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease.

Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2005 Nov;26(5):969-72.

4.

Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.

Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.

Intern Med. 2007;46(11):771-4. Epub 2007 Jun 1.

5.

[Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement].

Ohno N, Fujiyama S, Ooi M, Haraguchi K, Tokunaga M, Uozumi K, Tsubouchi H.

Nihon Naika Gakkai Zasshi. 2007 May 10;96(5):988-90. Japanese. No abstract available.

PMID:
17564092
6.

Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.

Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T.

Haematologica. 2007 Jun;92(6):857-8.

7.
8.

A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6.

Kadavath S, Zapantis E, Zolty R, Efthimiou P.

Int J Rheum Dis. 2014 Mar;17(3):336-40. doi: 10.1111/1756-185X.12324. Epub 2014 Feb 28. Review.

PMID:
24581387
9.

[Immunotherapy using IL-6 receptor as the target].

Nishimoto N.

Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):399-404. Review. Japanese. Erratum in: Nihon Rinsho Meneki Gakkai Kaishi. 2008 Dec;31(6):423.

10.

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.

Mohammed A, Janku F, Qi M, Kurzrock R.

J Med Case Rep. 2015 Feb 28;9:45. doi: 10.1186/s13256-015-0517-8.

11.

Siltuximab: a new option for the management of Castleman's disease.

Barquero N.

Drugs Today (Barc). 2015 Jan;51(1):21-8. doi: 10.1358/dot.2015.51.1.2234002. Review.

PMID:
25685858
12.

A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.

Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K.

J Korean Med Sci. 2010 Sep;25(9):1364-7. doi: 10.3346/jkms.2010.25.9.1364. Epub 2010 Aug 12.

13.

Cutaneous castleman's disease responds to anti interleukin-6 treatment.

Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R.

Mol Cancer Ther. 2007 Sep;6(9):2386-90. Epub 2007 Aug 31.

14.

Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.

Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S.

Intern Med. 2012;51(21):3061-6. Epub 2012 Nov 1. Review.

15.

A rare association of Castleman's disease and nephrotic syndrome.

Tazi I, Rachid M, Quessar A, Benchekroun S.

Saudi J Kidney Dis Transpl. 2011 Jan;22(1):116-9.

16.

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K.

Blood. 2000 Jan 1;95(1):56-61.

17.

[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].

Ohsugi Y, Tsuchimoto N.

Nihon Yakurigaku Zasshi. 2005 Dec;126(6):419-25. Review. Japanese. No abstract available.

PMID:
16462093
18.

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R.

J Clin Oncol. 2010 Aug 10;28(23):3701-8. doi: 10.1200/JCO.2009.27.2377. Epub 2010 Jul 12.

PMID:
20625121
19.

[Dyspnoea, cough and B symptoms in a 40-year-old woman].

Wolfensberger A, Benz R, Russi EW, Tinguely M, Keller C, Gerber B.

Internist (Berl). 2013 Aug;54(8):1011-5. doi: 10.1007/s00108-013-3327-3. German.

PMID:
23836253
20.

Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.

Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, Mizutani C, Ukyo N, Hirata H, Tsudo M.

Tohoku J Exp Med. 2015 Aug;236(4):289-95. doi: 10.1620/tjem.236.289.

Supplemental Content

Support Center